Despite considerable pressure directed squarely at biotech innovators from politicians of every stripe, biotech executives remained focused on finding the medicines of tomorrow at the BIO CEO & Investor Conference. New York, host of the event for the past 21 years, continues to be a premier biotech hub, attracting the industry’s most active investors. The conference concluded today having drawn nearly 1300 attendees representing 30 countries, making the event a global attraction.
A record number of investors—over 660—registered to learn about the latest biotech trends and to search for opportunities to turn technology into life-saving treatments. More than 130 biotechnology and pharmaceutical companies delivered 13-minute pitches showcasing their pipeline, R&D activities, business objectives and investment goals. Information was also shared through face-to-face meetings scheduled by BIO’s One-on-One Partnering™ system which was in full swing, scheduling almost 3,000 meetings—a record for this 21st annual event.
The two-day event drew a diverse roster of panelists and fireside chat speakers, including an impressive group of thought leaders from seven top tier investment banks who provided their perspective on what can be expected in the near term for the biotech market. On the policy side, BIO’s President and CEO Jim Greenwood, moderated a panel of experts exploring the impact of the Trump Administration’s proposal to require “foreign reference” pricing for medicines covered under Medicare Part B. Other panel sessions discussed the latest biotech trends including new treatments for diabetes and obesity, attacking the opioid epidemic, and advances in cancer and Alzheimer’s treatments.
To see what attendees are saying about this unique event, we talked with a few to get their impressions and feedback: